Milly Gaines
The latest diet pill is amycretin, developed by Novo Nordisk. In an early-stage clinical trial, participants taking amycretin lost up to 13% of their body weight over 12 weeks. The pill is currently in Phase 1 of the clinical trial and has not been subjected to external scientific scrutiny. However, the results are promising and justify further clinical research. Other recent weight loss drugs include Zepbound, Mounjaro, Wegovy, and Mysimba. These drugs are administered through injections and have shown significant weight loss results.
| Characteristics | Values |
|---|---|
| Name | Orforglipron |
| Manufacturer | Lilly |
| Pill Type | GLP-1 receptor agonist |
| Target Group | Diabetes patients |
| Dosage | Daily |
| Side Effects | Diarrhea, nausea, vomiting, constipation |
| Comparisons | Tirzepatide (Mounjaro), Wegovy, Ozempic |
| Success Rate | Lowered A1C and helped lose weight |
| Market Potential | $100 billion by 2030 |
| Competitors | Novo Nordisk, Pfizer, Roche, Viking Therapeutics |
| Alternative Pills | Xenical, Qsymia, Rybelsus, Amycretin, Elcella |
Explore related products
What You'll Learn
Novo's amycretin pill
The latest diet pill to enter the market is orforglipron, which has been shown to be effective in lowering blood sugar and aiding weight loss. However, the focus of this response will be on the promising new weight loss pill by pharmaceutical giant Novo, called Novos amycretin pill.
Novos amycretin pill
Novo, a leading diabetes drug manufacturer, has developed a weight loss pill called amycretin. In a Phase 1 clinical trial, participants taking one or two 50 mg amycretin pills per day lost up to 13% and 10% of their body weight, respectively, over a 12-week period. This is a significant amount of weight loss in a short period, indicating the pill's potential effectiveness.
Amycretin is currently in the early stages of development, and further clinical research is needed to validate its efficacy and safety. Novo is considering whether to proceed directly to a large-scale Phase 3 trial, which would be the final stage of testing before seeking regulatory approval. The decision will be based on data from the ongoing early-stage trial, with results expected in 2025.
Novo's focus on obesity drugs has been a strategic move, propelling the company to become one of Europe's most valuable pharmaceutical companies. The development of amycretin is part of a broader industry trend, with pharmaceutical giants like Pfizer, Roche, and Viking Therapeutics also racing to develop weight loss pills and capture a share of this lucrative market.
While injectable anti-obesity drugs, such as Zepbound and Wegovy, currently dominate the market, pills offer a more accessible and cost-effective alternative. They do not require refrigeration and are easier to administer, making them more widely available, especially in regions with limited access to injectable medications.
However, it is important to note that weight loss pills may come with specific dietary restrictions, such as taking the pill on an empty stomach, and may need to be taken daily. Additionally, pills may require a higher dosage of the active ingredient to achieve the desired effect, which could impact supply and manufacturing costs.
Novos amycretin pill shows promising early results, and the company's decision to accelerate development will be highly anticipated by those seeking alternative weight loss treatments.
Lockdown Eating Habits: A Time for Dietary Change
You may want to see also
Explore related products
Zepbound (tirzepatide) injection
Zepbound (tirzepatide) is an FDA-approved prescription medicine for adults with obesity or overweight individuals with at least one weight-related condition. It is administered through a once-weekly injection under the skin of the stomach (abdomen), thigh, or upper arm. The dosage is typically increased over four to 20 weeks to achieve the target dosages of 5 mg, 10 mg, or 15 mg once weekly. The maximum dosage of Zepbound is 15 mg once weekly.
Zepbound contains tirzepatide, which is also found in Mounjaro, a drug used to improve blood sugar in adults with type 2 diabetes. It works by reducing appetite and making individuals feel full more quickly and for longer, thereby reducing food intake. In clinical trials, patients who used Zepbound lost an average of 48 lbs or 20.9% of their body weight over 72 weeks, compared to 7.1 lbs or 3.1% for a placebo.
Zepbound should be used in conjunction with a reduced-calorie diet and increased physical activity. It is not suitable for individuals with a history of serious allergic reactions to tirzepatide or its ingredients. Common side effects include nausea, diarrhea, vomiting, constipation, stomach pain, indigestion, injection site reactions, fatigue, allergic reactions, belching, hair loss, and heartburn. More severe side effects may include stomach problems, kidney problems, gallbladder issues, and thyroid tumors, including thyroid cancer.
Zepbound is part of a market for injectable anti-obesity drugs, which also includes Wegovy, Ozempic, and Mounjaro. These drugs have been found to reduce the risk of heart disease, sleep apnea, and other chronic conditions associated with weight. However, they have also been linked to various side effects, ranging from mild gastrointestinal issues to more severe complications like blood clots, eye disease, and hair loss.
Hair Regrowth: Dieting and the Waiting Game
You may want to see also
Explore related products
Wegovy and Ozempic injections
The latest new diet pill is called orforglipron, which is a daily pill for diabetes patients that helps lower blood sugar and aids weight loss. However, the market for injectable anti-obesity drugs is currently dominated by Zepbound and Wegovy.
Wegovy and Ozempic are prescription drugs that aid weight loss and weight management. They are both injectables, injected once a week, and come in different strengths. They are made by the same pharmaceutical company, Novo Nordisk, and are both semaglutides.
Wegovy
Wegovy is FDA-approved for weight management in certain children aged 12 and older and adults with obesity or those who are overweight and have health problems related to excess weight. It is available in pre-filled single-dose pens with doses of 0.25 mg, 0.5 mg, 1 mg, 1.7 mg, or 2.4 mg. The treatment starts with a dose of 0.25 mg once weekly for four weeks, after which the dose is gradually increased until reaching a maintenance dose of 2.4 mg weekly.
Ozempic
Ozempic is approved for people with Type 2 diabetes and is available in pre-loaded single-dose pens with varying dosages of 0.25 mg, 0.5 mg, 1 mg, or 2 mg per injection. The dose can be slowly increased, up to a maximum of 2 mg per week, if needed. Doctors may prescribe Ozempic off-label to aid weight loss in certain children.
Side Effects
Gastrointestinal problems are the most common side effects of both drugs since they can slow down people’s digestive systems. During clinical trials, some participants experienced nausea, diarrhea, vomiting, constipation, abdominal pain, headache, fatigue, indigestion, dizziness, bloating, and gas. A small percentage of people who take the drugs can also suffer from a diabetes eye complication called retinopathy.
Net Carb Consumption: How Many is Too Many?
You may want to see also
Explore related products
Mounjaro (tirzepatide) injection
Mounjaro (tirzepatide) is an injectable prescription medicine for adults with type 2 diabetes. It is used alongside diet and exercise to improve blood sugar (glucose) levels. It is available as a pre-filled single-dose pen in 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, or 15 mg per 0.5 mL injection. It is administered once weekly, at any time of the day, and should be injected under the skin (subcutaneously) of the stomach (abdomen), thigh, or upper arm. It should not be injected into a muscle (intramuscularly) or vein (intravenously).
Mounjaro is not recommended for those with a personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia type 2 (MEN 2). It may also cause serious side effects, including inflammation of the pancreas (pancreatitis) and thyroid cancer. Other possible side effects include low blood sugar (hypoglycaemia), serious allergic reactions, and dehydration leading to kidney problems.
Mounjaro has been shown to aid weight loss and maintain weight loss when combined with diet and exercise. It works by activating two gut hormone receptors, GIP and GLP-1, to manage blood sugar. This stimulates insulin release when glucose is high, reduces liver glucagon production, slows stomach emptying to control post-meal sugar spikes, and increases feelings of fullness.
The market for injectable anti-obesity drugs is expected to grow significantly, reaching $100 billion in sales by 2030. Mounjaro, Zepbound, Ozempic, and Wegovy are popular injectable medications that target a group of hormones known as incretins, which include GLP-1. These medications have been effective in treating diabetes and obesity and reducing the risk of related chronic conditions, such as heart disease, sleep apnea, kidney and liver diseases, and even Alzheimer's.
Navigating the Pre-Op Liquid Diet: Strategies for Success
You may want to see also
Explore related products
Qsymia pill
Qsymia is a prescription medicine that contains phentermine and topiramate extended-release. It is a combination medication used to help with weight loss. It is approved for people over 12 who are considered obese and for some adults who are overweight with weight-related medical problems like high blood pressure, type 2 diabetes, or high cholesterol. It is the #1 prescribed branded oral weight-management medication in adults and is FDA-approved for weight management in children ages 12-17.
Qsymia should be used with a reduced-calorie diet and increased physical activity. It is not known if Qsymia changes the risk of heart problems or strokes or death due to these problems. It is also not known if Qsymia is safe and effective when taken with other prescription and over-the-counter medicines, or herbal weight loss products. It is not known if Qsymia is safe and effective in children under 12 years old.
Qsymia may cause problems with concentration, memory, and speech. It can also cause eye pain or changes in vision. It can also slow down how fast your child grows. This risk is increased in children who get metabolic acidosis while taking Qsymia. Metabolic acidosis happens when there is too much acid in the blood.
Qsymia may also cause kidney problems and kidney stones in some people. It can also lead to decreased sweating and body temperature increases. Some people may need to be treated in a hospital if this happens. Low potassium levels can also happen in people who take Qsymia, especially if they take other medicines that lower potassium levels.
Qsymia is available only through the Qsymia REMS (Risk Evaluation and Mitigation Strategies) program because of the risk of birth defects if taken during pregnancy. It should not be taken by patients who are pregnant, planning to become pregnant, or become pregnant during treatment.
Add These Foods to Your Diet for a Health Boost
You may want to see also
Frequently asked questions
The latest diet pill is Orforglipron, which is a GLP-1 receptor agonist. It is expected to move forward for approval in 2026.
Side effects of Orforglipron include diarrhea, nausea, vomiting, and constipation. However, there were no recorded liver issues.
Orforglipron targets a group of hormones known as incretins, which include GLP-1. It works to curb appetite and reduce food intake.
Participants in a Phase 2 trial lost up to 14.7% of their body weight in eight months.
Yes, there are several other weight loss pills on the market or in development, including Wegovy, Ozempic, Rybelsus, Xenical, Qsymia, and Amycretin.
